1. An active pixel sensor circuit comprising:
a sensor for receiving light;
a reset transistor having a source coupled to the sensor for resetting the sensor;
a source-follower transistor having a gate coupled to the source of the reset transistor; and
a row-selector transistor having a gate coupled to a drain of the reset transistor, a drain coupled to a source of the source-follower transistor, and a source coupled to a pixel line.
2. The active pixel sensor circuit of claim 1, wherein the source-follower transistor has a drain coupled to the drain of the reset transistor.
3. The active pixel sensor circuit of claim 1, wherein the sensor comprises a photodiode, a pinned diode, or a photogate.
4. The active pixel sensor circuit of claim 1 further comprising a transfer transistor coupled between the sensor and the source of the reset transistor for controlling transfer of photoelectric charge of the sensor.
5. The active pixel sensor circuit of claim 4, wherein the transfer transistor is an NMOS transistor having a source coupled to the sensor and a drain coupled to the source of the reset transistor.
6. The active pixel sensor circuit of claim 5, wherein the reset transistor, the source-follower transistor, and the row-selector transistor are NMOS transistors.
7. A method for controlling an active pixel sensor circuit, the method comprising:
turning on a reset transistor coupled to a sensor and a row-selector transistor having a drain coupled to a source of a source-follower transistor when resetting the sensor, the source-follower transistor having a gate coupled to a source of the reset transistor;
turning off the reset transistor and the row-selector transistor when the sensor is at an initial exposure time;
turning on the row-selector transistor when reading a light signal received by the sensor; and
turning on the reset transistor when reading a reset signal;
wherein parasitic capacitance at the gate of the source-follower transistor when resetting the sensor is the same as when reading the reset signal.
8. A method for controlling an active pixel sensor circuit, the method comprising:
turning on a reset transistor coupled to a sensor, a row-selector transistor having a drain coupled to a source of a source-follower transistor, and a transfer transistor coupled between the reset transistor and the sensor when resetting the sensor, the source-follower transistor having a gate coupled to a source of the reset transistor;
turning off the reset transistor, the row-selector transistor, and the transfer transistor when the sensor is at an initial exposure time;
turning on the reset transistor and the row-selector transistor when reading a reset signal; and
turning off the reset transistor and turning on the transfer transistor when reading a light signal received by the sensor;
wherein parasitic capacitance at the gate of the source-follower transistor when resetting the sensor is the same as when reading the reset signal.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of Formula (1):
or pharmaceutically acceptable salts thereof, wherein:
X is O or S;
Y is NR, O or S;
one of R1 or R2 is H or C1-6 alkyl, and the other of R1 or R2 is phenyl; said phenyl is optionally substituted with halo, halogenated C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl, C3-7 cycloalkyl, an optionally halogenated C1-6 alkoxy, or OR5; or
R1 and R2 together with Ring A may form
R3 is \u2014O(CR72)m\u2014CO2\u2014R or \u2014(CR72)m\u2014CO2\u2014R;
R4 is C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl, halo, or C1-6 alkoxy; or
R3 and R4 or two adjacent R4 together with the carbon atoms to which they are attached to may form a 4-7 membered saturated or unsaturated carbocyclic ring or heterocyclic ring containing N, O or S; wherein said carbocyclic ring or heterocyclic ring is substituted with \u2014O\u2014(CR72)m\u2014CO2\u2014R or \u2014(CR72)m\u2014CO2\u2014R;
R5 is a C3-7 cycloalkyl, or a 5-7 membered aryl, heteroaryl or heterocyclic ring containing N, O or S, each of which is optionally substituted;
R6 is a substituent at any position in Ring B or Ring C, and is halo, an optionally halogenated C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl, an optionally halogenated C1-6 alkoxy, or OR5;
each R7 is H, C1-6 alkyl, C2-6 alkenylene or OR;
each R is H or C1-6 alkyl;
Ring B is a 4-7 membered saturated or unsaturated carbocyclic ring or heterocyclic ring containing N, O or S;
Ring C is aryl;
k is 0-4; and
m and n are independently 0-6.
2. The compound of claim 1, wherein R1 and R2 together form
3. The compound of claim 1, wherein k is 1 and R4 is C1-6 alkyl or C1-6 alkoxy.
4. The compound of claim 1, wherein R3 and R4 or two adjacent R4 together with the carbon atoms to which they are attached to form
5. The compound of claim 1, wherein n is 0.
6. The compound of claim 1, wherein m is 0-3.
7. The compound of claim 1, wherein said compound comprises Formula (2):
wherein p is 0-5; and
R6 is halo, an optionally halogenated C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl, an optionally halogenated C1-6 alkoxy, or OR5.
8. The compound of claim 7, wherein p is 1-2 and R6 is halo.
9. The compound of claim 8, wherein said halo is chloro.
10. The compound of claim 7, wherein k is 1 and R4 is C1-6 alkyl or C1-6 alkoxy.
11. The compound of claim 7, wherein R3 and R4 or two adjacent R4 together with the carbon atoms to which they are attached to form
12. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1.
13-18. (canceled)
19. A method for modulating G protein-coupled receptor 120 (GPR120) comprising administering to a cell or tissue system, a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent, thereby modulating said GPR120.
20. The method of claim 19, wherein said compound is a GPR120 agonist.
21. A method for treating a condition mediated by G protein-coupled receptor 120 (GPR120), comprising administering to a mammalian subject, an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, and optionally with a second therapeutic agent, thereby treating said condition.
22. The method of claim 21, wherein said condition is diabetes, dyslipidemia, obesity or anorexia.
23. The method of claim 22, wherein said diabetes is diabetes mellitus.
24. The method of claim 22, wherein said dyslipidemia is hyperlipidemia.